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Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that primarily
strikes the elderly. Studies in both humans and animal models have linked the consumption of
cholesterol and saturated fats with amyloid-β (Aβ) deposition and development of AD. Yet, these
studies did not examine high fat diets in combination with reduced carbohydrate intake. Here we
tested the effect of a high saturated fat/low carbohydrate diet on a transgenic mouse model of AD.
Results: Starting at three months of age, two groups of female transgenic mice carrying the
"London" APP mutation (APP/V717I) were fed either, a standard diet (SD) composed of high
carbohydrate/low fat chow, or a ketogenic diet (KD) composed of very low carbohydrate/high
saturated fat chow for 43 days. Animals fed the KD exhibited greatly elevated serum ketone body
levels, as measured by β-hydroxybutyrate (3.85 ± 2.6 mM), compared to SD fed animals (0.29 ±
0.06 mM). In addition, animals fed the KD lost body weight (SD 22.2 ± 0.6 g vs. KD 17.5 ± 1.4 g, p
= 0.0067). In contrast to earlier studies, the brief KD feeding regime significantly reduced total
brain Aβ levels by approximately 25%. Despite changes in ketone levels, body weight, and Aβ levels,
the KD diet did not alter behavioral measures.
Conclusion: Previous studies have suggested that diets rich in cholesterol and saturated fats
increased the deposition of Aβ and the risk of developing AD. Here we demonstrate that a diet
rich in saturated fats and low in carbohydrates can actually reduce levels of Aβ. Therefore, dietary
strategies aimed at reducing Aβ levels should take into account interactions of dietary components
and the metabolic outcomes, in particular, levels of carbohydrates, total calories, and presence of
ketone bodies should be considered.
Background
Alzheimer's disease (AD) is an age-associated neurode-
generative disease that is very common in the US, affect-
ing up to 50% of people between the ages of 75 to 84 years
[1]. The number of cases of AD will increase dramatically
in the next 50 years due to the aging population of the
developed world and will present an increasing medical
challenge [2]. Clinically, AD is characterized by
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progressive impairment in memory and language and is
frequently accompanied by behavioral symptoms, such as
anxiety and depression. Pathologically, AD is character-
ized by accumulation of senile plaques, dystrophic neur-
ites, and neurofibrillar tangles. The plaques contain large
amounts of the β-amyloid (Aβ) peptide derived from
cleavage of the amyloid precursor protein (APP). Muta-
tions in APP that result in increased generation of a partic-
ular form of Aβ (Aβ42) have been identified in familial
cases of AD and this connection has led to the hypothesis
that Aβ is central to the etiology of AD (for review see [3]).
However, APP functions as a vesicular transport protein
and the etiology of the disease may not be directly related
to Aβ, but rather to abnormal cleavage of APP and failure
to efficiently move vesicles in the axons [4]. While the pre-
cise role of Aβ in AD remains unresolved, it is clear that Aβ
serves as a pathological marker for the disease.
The development of AD and the accumulation of Aβ have
been linked to dietary factors. Diets rich in saturated fat
have been repeatedly implicated in epidemiological stud-
ies [5-8], though they have been difficult to reproduce [9].
In addition, several experiments in mouse models seem to
confirm the link between lipid rich diets and AD. Using
transgenic mouse models of AD several groups have
reported that high fat diets or diets with added cholesterol
increased levels and deposition of the Aβ peptide [10-14].
However, these studies did not examine the effects of lipid
rich diets in combination with low carbohydrate intake.
Diets that contain very low carbohydrate and high fat con-
tent are well known to induce the hepatic production of
ketone bodies (β-hydroxybutyrate, acetoacetate and ace-
tone) and are often referred to as ketogenic diets (KD).
Ketogenic diets in some aspects mimic starvation and
were developed for use in humans to treat epilepsy based
on the long record of observations that fasting reduces sei-
zures (for review see [15]). The experimental KD is calorie
restricted and has fixed composition and is thus different
from low carbohydrate diets used for weight loss, which
are usually ad lib and variable in composition. Despite
these differences, low carbohydrate diets may also be
effective in preventing seizures and may work through
similar mechanisms as a KD [16]. The precise mechanism
for the anti-convulsant properties of these diets is still
unknown. The low carbohydrate content of both diets
induce many metabolic changes that may be protective,
such as elevated circulating ketone body levels, increased
oxidation of fats, changes in protein metabolism, and
changes in gene expression [17,18].
Results
The present study tested experimentally the effects of a KD
composed of extremely low carbohydrate and very high
saturated fat content in a transgenic mouse model of AD.
The mice express a human APP gene containing the "Lon-
don" APP mutation (APP/V717I) driven by a thy-1 gene
promoter. APP/V717I transgenic mice produce significant
levels of soluble Aβ in the brain as early as 3 months of age
and exhibit extensive plaque deposition by 12–14
months. The animals demonstrate early behavioral defi-
cits and represent a model of early-onset familial AD [19].
Diet
Sixteen female APP/V717I mice were fed ad libitum on a
standard diet (SD) comprised of a high carbohydrate/ low
fat chow (Muracon-G chow: 35% carbohydrate, 21% pro-
tein, 4.5% fat, 39.5% water, fiber, and ash). The predom-
inant fatty acid in Muracon-G is linoleic acid (18:2) and it
comprises 1.4% of the chow by weight. At three months
of age half the group (8 animals) was switched to a
ketogenic diet (KD) comprised of very low carbohydrate/
high fat chow while the remaining 8 animals remained on
the SD. In both cases the animals had free access to chow
at all times and intake was not experimentally limited. For
the KD we used Bio-Serv Inc. F3666 chow: 0.76% carbo-
hydrates, 8% protein, 79% fat, 12% water, fiber, and ash.
F3666 is a ketogenic chow composed of lard, butter fat,
dextrose, casein, fiber, corn oil, mineral mix, and a vita-
min mix. F3666 is rich in saturated fats. Greater than 29%
of the F3666 chow is composed of saturated fats by
weight: 2.4% myristic acid (C14:0), 18.9% palmitic acid
(C16:0), and 8.4% stearic (C18:0) (see Table 1). The ani-
mals fed the F3666 chow are referred to as the KD group.
The mice that remained on the Muracon-G chow are
referred to as the SD group.
KD diet and weight loss
During the first 7 days many of the animals in the KD
group were reluctant to eat the new chow and lost weight
(Figure 1). To improve consumption and mitigate weight
loss, SD chow was mixed with KD chow at a ratio of 1:3
starting at day 16 until day 20. For the seven days follow-
ing day 20 the amount of SD chow was reduced to a few
crumbs sprinkled over the KD chow. After day 28 the ani-
mals were returned to KD chow only. The mixed chow
restored body weights of the KD group to approximately
the level of the SD group, at about 20 grams (Figure 1).
When the animals were fed KD chow exclusively, body
weights again dropped, yet tended to stabilize at approxi-
mately 18 grams (Figure 1). At the conclusion of the
experiment mean weights were significantly different (SD
22.2 ± 0.6 g vs. KD 17.5 ± 1.4 g, p = 0.0067).
KD diet elevates serum β-hydroxybutyrate levels
To measure the effectiveness of the chow to induce a
ketogenic state, blood samples were taken weekly and
examined for levels of β-hydroxybutyrate (BHB). Eight
days after switching the chow animals in the KD group
had greatly elevated BHB levels compared to the SD groupNutrition & Metabolism 2005, 2:28 http://www.nutritionandmetabolism.com/content/2/1/28
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(SD 0.26 ± 0.023 mM vs. KD 8.94 + 1.8 mM, p < 0.0001,
Figure 2), possibly due to some animals not eating. As
expected, feeding the mixed chow on days 16–28 reduced
serum ketone bodies (Figure 2). Yet, at all time points
examined after day 0 ketone levels were significantly
greater in the KD fed group compared to the SD group
(Figure 2). The average serum BHB concentration over the
course of the experiment was elevated in the KD group
compared to the SD group (SD 0.29 ± 0.06 mM vs. KD
3.85 ± 1.1 mM, p < 0.0078). The elevated ketone levels in
the KD group suggested that a metabolic shift toward fat
utilization had occurred in these animals.
Cognitive testing
After 38 days on the diet animals were tested for behavio-
ral deficits using object recognition tests as previously
described [20], see methods. Despite the differences in
chow, BHB levels, and weight loss, no difference in behav-
ioral measures were detected between the groups (Table
2).
Table 1: Fatty acid profile of F3666 (KD) chow
Fatty acid gm/kg gm/kg
C4 Butanoic 4.59 C16 Palmitic 189.03
C6 Hexanoic 3.19 C16:1 cis-9-Hexadecenoic 28.18
C8 Octanoic 2.99 C17 Heptadecanoic 2.38
C10 Decanoic 4.39 C17:1 Heptadecenoic 1.43
C10:1 Decenoic 0.80 C18 Stearic 84.79
C12 Lauric 6.41 C18.1 Oleic 298.34
C12:1 cis-9-Dodecenoic 0.40 C18:2 Linoleic 119.44
C14 Myristic 24.43 C18:3 Linolenic 6.33
C14:1 cis-9-Tetradecenoic 6.14 C20 Eicosanoic 1.18
C15 Pentadecanoic 0.48 C20:1 cis-11-Eicosenoic 3.80
Average weight in grams of each group during the course of  the experiment Figure 1
Average weight in grams of each group during the course of 
the experiment. Blue squares represent standard diet (SD) 
group. Red circles represent ketogenic diet (KD) group. 
Error bars represent standard error of the mean. Days signify 
time in days from start of diet change. Animals on KD lost 
weight. To mitigate weight loss and improve feeding a small 
amount of SD chow was mixed with KD chow during the 
second week and then removed on the third week, see 
methods.
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Ketogenic diet induces ketone bodies production Figure 2
Ketogenic diet induces ketone bodies production. Standard 
diet (SD) group shown in blue, ketogenic diet (KD) group 
shown in red, error bars represent standard error of the 
mean. Serum β-hydroxybutyrate (BHB) levels in mM. * indi-
cates p < 0.05 between KD and SD group. Days signify time 
in days from start of diet change. Serum β-hydroxybutyrate 
levels were significantly elevated in KD group at all time 
points after day 0. Bar indicates period of mixed chow for 
KD group.
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Aβ levels
At four months of age APP/V717I mice do not possess Aβ
positive plaques and all the Aβ is present in the soluble
fraction [19]. Therefore, 43 days after dietary change levels
of soluble Aβ in the brain were measured in both groups
of animals. Brain homogenate was isolated as previously
described [20], see methods. One hemisphere from each
animal was analyzed for both Aβ 40 and 42 levels using
the Amyloid Aβ40 or Aβ42 ELISA High Sensitivity Kit (The
Genetics Company, Zurich, Switzerland). Levels of both
soluble Aβ 40 and 42 were found to be significantly lower
in the KD fed group (Figure 3). In cases of familial AD
excess Aβ42 is produced relative to Aβ40 thereby increas-
ing the Aβ 42/40 ratio. We examined the ratio of Aβ42 to
Aβ40 and found no difference between groups (SD 0.51 ±
0.024 vs. KD 0.56 ± 0.026, p= 0.2872), suggesting that the
diet did not alter cleavage sites on APP, but instead pro-
moted a general lowering of Aβ species.
Total protein levels were examined to determine if a gen-
eral decline in brain protein in the KD group could
explain the decrease in Aβ levels. However, protein levels,
measured as mg/ml of brain homogenate, did not differ
between the two groups (SD 0.56 ± 0.035 mg/ml vs. KD
0.51 ± 0.017 mg/ml, p= 0.213). Since most (though not
all) of the animals in the KD group lost weight, the ani-
mals with the greatest weight loss may have been expected
to have the lowest Aβ levels. However, the levels of Aβ40
or Aβ42 did not correlate with weight change across all
groups (Aβ40 r = 0.16, p = 0.20; Aβ42 r = 0.05, p = 0.49)
or in the KD group alone (Aβ40 r < 0.0001, p = 0.96; Aβ42
r = 0.09, p = 0.62). Both of these measures suggest that the
Aβ lowering effect is not the result of a general lowering of
protein levels due to weight loss.
A better measure of the effectiveness of the ketogenic diet
was serum BHB levels, since all the animals in the KD
group exhibited elevated BHB levels. When Aβ40 and 42
levels from all animals were correlated with the average
serum BHB over the course of the experiment, a signifi-
cant correlation was observed (Aβ40 r = 0.42, p = 0.016;
Aβ42 r = 0.42, p = 0.016). However, this correlation was
most likely driven by the large differences in BHB and Aβ
levels between the two groups, since there was no signifi-
cant correlation between Aβ and BHB levels in the KD
group alone (Aβ40 r = 0.083, p = 0.58; Aβ42 r = 0.15, p =
0.46).
Discussion
This study demonstrated the unexpected result that a brief
treatment with a low carbohydrate/high saturated fat diet
reduced total Aβ levels in a mouse model of Alzheimer's
disease. Previous studies had suggested that diets rich in
saturated fats or cholesterol increased both the produc-
tion and deposition of Aβ in mouse models of AD, lead-
ing to the suggestion that diets rich in lipids were a factor
in AD [10,12-14]. However, these diets were not low car-
bohydrate diets. In the high cholesterol diets, cholesterol
was added to the diet without reduction in other compo-
nents [10,14]. In the studies of high fat diets, carbohy-
drate content was still relatively high. For example, Ho et
al. used a diet of 60% fat, 20% carbohydrate, 20% protein.
This diet was sufficiently high in carbohydrate to cause
large increases in body weight in the animals [11].
The interaction of different macronutrients, in particular
fats and carbohydrates, is known to influence the meta-
bolic state of the animal. For example, Marsset-Baglieri et
al. examined if fat in the diet alone was sufficient to shift
energy balance toward fat storage. Yet, rats fed ad libitum
Ketogenic diet reduces Aβ40 and Aβ42 Figure 3
Ketogenic diet reduces Aβ40 and Aβ42. Aβ levels as ng/g of 
brain tissue. Standard diet (SD) group shown in blue, 
ketogenic diet (KD) group shown in red, error bars repre-
sent standard error of the mean. SD chow Aβ40 1.72 ± 0.12 
ng/g vs. KD chow Aβ40 1.28 ± 0.09 ng/g, p= 0.012. SD chow 
Aβ42 0.88 ± 0.05 ng/g vs. KD chow Aβ42 0.71 ± 0.0.4 ng/g, p 
= 0.016.
Table 2: Recognition Index
Test SD KD p value
RI by time 56.2 ± 5.7 56.7 ± 8.2 0.963
Curiosity by time 10.0 ± 2.7 11.6 ± 6.5 0.803
RI by frequency 49.3 ± 3.6 54.6 ± 9.7 0.628
Curiosity by frequency 14.4 ± 2.3 11.9 ± 3.9 0.530
Mean velocity 3.8 ± 0.4 4.5 ± 0.8 0.447
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high fat (50%) diets devoid of carbohydrates did not
increase energy intake and did not gain in body adiposity,
while animals fed high fat diets (30%) in the presence of
carbohydrates (56%) increased energy intake and gained
in body fat [21]. Such studies support the view that when
fat and carbohydrates are consumed simultaneously, the
carbohydrates stimulate insulin secretion and thereby
promote storage of fat (for recent review see [22]). There-
fore, it is important to consider the macronutrient profile
of the diet when examining the effects of dietary fat on
biological processes.
In the present study, transgenic animals were fed ad libi-
tum a very high fat (79%) diet that was practically devoid
of carbohydrates (0.76%). The KD resulted in ketone
body production, weight loss, and decreased Aβ levels.
Hence, the data presented here suggests that it may not be
fats in the diet that increases Aβ levels, but perhaps levels
of total calories, carbohydrates, or the metabolic state of
the animal.
Epidemiological studies in humans have implicated satu-
rated fats in the diet as a risk factor for Alzheimer's disease.
For example, Kalmijn et al. correlated eating habits with
incidence of dementia after a two year follow-up in a large
study of 5,386 subjects in Rotterdam, NL. The results from
this analysis led the author to suggest that diets rich in sat-
urated fats and cholesterol increased the risk of several
types of dementia [5]. However, after a 6 year follow-up of
this same population, no correlation between dementia
and fat intake could be identified, leading the authors to
conclude "High intake of total, saturated, and trans fat
and cholesterol and low intake of MUFA, PUFA, n-6
PUFA, and n-3 PUFA were not associated with increased
risk of dementia or its subtypes." [9]. More recent studies
have also examined the link between dietary fat and
cognitive decline. In a study of 2,560 participants ages 65
and older in the Chicago Health and Aging project, fat
intake was measured by food questionnaire and corre-
lated with cognitive testing examined after a 3 and 6 year
follow- up. This large study found only weak trends
between saturated fat and cholesterol intake and cognitive
decline [7]. Both the rodent and human studies highlight
the complications of trying to link complex environmen-
tal factors, such as eating habits or macronutrient intake,
with dementia and Alzheimer's disease. In particular, one
complicating factor in the human studies is the normal
consumption of large amounts of carbohydrates in mod-
ern diets.
The present study demonstrates that, contrary to expecta-
tions, transgenic mice fed ab libitum a very low carbohy-
drate/high saturated fat diet present lower levels of Aβ
after only 43 days of dietary change. The KD group exhib-
ited low levels of both Aβ40 and the more amyloidic
Aβ42, suggesting that the KD diet did not change or
increase the efficiency of cleavage sites within APP.
Instead the data suggests the KD regime either reduced
processing of APP or increased degradation of Aβ species.
Most of the animals administered the ketogenic diet lost
body weight as well as exhibited reduced Aβ levels. How-
ever, the reduced Aβ levels may not have been due to a
general lowering of protein content. Total brain protein
levels did not differ between the groups and Aβ levels did
not correlate with weight loss. Interestingly, despite
change in diet, weight loss, and Aβ levels, no change in
cognitive performance was observed (Table 2). This obser-
vation agrees with the general finding that KD diets are
not harmful to mice [23]. Also, the finding that reduction
in Aβ did not improve cognitive performance may be due
to the modest lowering of levels under these conditions
and longer treatment may be required.
The KD diet was developed to mimic a starvation response
in animals without reducing calories to harmful levels
[15]. In this way a KD is similar to caloric restriction (CR)
regimes that have been used in many species to alter aging
and increase some forms of stress resistance. CR typically
reduces calories 30–40% compared to ad libitum fed ani-
mals and has numerous positive effects on animal health
[24]. In the present study we did not attempt to restrict
calories in any way and the animals had free access to the
ketogenic chow at all times and intake was self limited.
However, since the animals were reluctant at first to eat
the KD chow and we observed weight loss in the KD
group, we cannot rule out the possibility that the Aβ low-
ering effects were due to CR.
Yet, CR and KD may work through similar mechanisms.
KD are well known to reduce insulin signaling and mimic
starvation, thereby increasing fatty acid oxidation and
promoting a catabolic state [17]. Similarly, CR is well
known to reduce serum insulin and IGF levels and much
of the benefit of CR may derive from this reduction in
insulin/IGF signaling (for review see [25]). For example,
decreased insulin/IGF-like signaling inhibits protein syn-
thesis and promotes protein degradation, which may lead
to the clearing of degradation-sensitive proteins, such as
amyloidic peptides.
Increasing evidence suggests a role for insulin/IGF-1 in
regulating APP and modulating Aβ levels. Receptors for
both insulin and IGF-1 are highly expressed in brain, espe-
cially in hippocampus and cortex, where they may influ-
ence learning and memory [26]. Insulin signaling in the
brain increases extracellular levels of Aβ by promoting
secretion [27] and inhibiting degradation by insulin-
degrading enzyme [28]. This view has also gained recent
support in humans. Fishel et al. demonstrated that
induced hyperinsulinemia in healthy elderly subjectsNutrition & Metabolism 2005, 2:28 http://www.nutritionandmetabolism.com/content/2/1/28
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elevated both serum and spinal fluid Aβ levels, suggesting
insulin plays a role in elevating Aβ, especially under con-
ditions such as type II diabetes [29].
Such an interpretation is consistent with recent studies
demonstrating similar Aβ lowering effects of a low carbo-
hydrate, caloric restriction (CR) regime in mice expressing
the "Swedish" form of APP (Tg2576 mice). In these
animals, lower levels of Aβ 40 and 42 were detected in
animals fed 30% less carbohydrates than ad libitum fed
animals. The Aβ lowering effect may have been due to
increased α-secretase and insulin degrading enzyme activ-
ity in the CR animals [30].
Alternatively, other physiologic changes may have
reduced Aβ levels in this study. The high levels of ketone
bodies alone may have contributed to increased protein
turnover. Ketone bodies added to cell culture have been
shown to lead to increased oxidation of proteins prone to
oxidative damage. The presence of damaged protein trig-
gers proteolysis of normally long lived proteins via chap-
erone-mediated autophagy [31]. Such a mechanism may
be at work in animals fed a ketogenic chow and exposed
to high levels of ketone bodies. Some support for this
model comes from the observation that elevated ketone
body levels correlated better with lowering of Aβ species
than did weight loss. In addition, ketone bodies may serve
as an efficient substrate for neuronal metabolism.
Previous studies have shown that acute elevation of
ketone bodies may improve cognitive performance in
some individuals with mild to moderate AD [32].
Conclusion
As the population of the developed world ages the inci-
dence of AD is predicted to increase dramatically and will
place a tremendous burden on health services [2]. Dietary
intervention represents a relatively safe and readily availa-
ble method to combat AD. Yet, the key dietary links
remain unclear. Much of the earlier work has focused on
the role of high fat or high cholesterol diets and their con-
tribution to AD. However, evidence suggests that the pri-
mary genetic risk factor for late onset AD, the epsilon4
allele of apolipoprotein E, may have been selected against
in populations with long historical exposure to agriculture
[33]. In addition, foods rich in carbohydrates are
relatively recent additions to the human diet and are likely
to be more evolutionarily discordant than high fat diets
[34]. Therefore, the recent evolutionary switch to high car-
bohydrate (HC) diets may play an important role in
development of AD. HC diets are well known to stimulate
insulin signaling and result in a suppression of lipid
metabolism [22]. Thus, such diets may lead to inappropri-
ate lipid environments in neurons, mis-cleavage of APP
and the resulting inhibition of cellular trafficking, and
ultimately increasing the risk of developing AD (for over-
view see [35]).
Methods
Animals
Sixteen APP [V717I] C57Bl × FVB female mice of 3
months of age were used for this study. Mice were housed
under a reversed day-night rhythm: 14 hours light/10
hours darkness starting at 7 p.m. in standard metal cages
type RVS T2 (area of 540 cm2). The number of mice per
cage was limited in accordance with legislation on animal
welfare. All mice were genotyped by polymerase chain
reaction (PCR) at the age of 3 weeks. Mice were blind ran-
domized and age-matched and had free access to pre-fil-
tered and sterile water (UV-lamp). Mice had free access to
either ketogenic (KD) (code F3666, Bio-Serv, Frenchtown,
US) or standard (SD) chow (Muracon-G, Trouw Nutri-
tion, Gent). The F3666 chow is a runny paste and was
given in special designed liquid food suppliers and was
refreshed daily. F3666 is a liquid chow and the animals
frequently spilled the chow in the cage. Also, since all the
animals in a given group were housed together in a single
cage, measuring chow intake per animal was not possible
and was not recorded. Due to some problems with weight
loss in animals in the KD group, these animals were fed a
mixed chow 1(SD):3(KD) starting at day 16 until day 20.
From days 21–27 the amount of SD chow was reduced to
a few crumbs sprinkled over the KD chow. After day 28 the
animals were returned to KD chow only. However, one
mouse in the KD group refused food intake and died
despite attempts of feeding via gavage. One control ani-
mal died during blood draw.
Blood collection and analysis
Blood was collected from anesthetized mice from either
the orbital plexus or via a heart puncture. β-hydroxybu-
tyrate levels were measured spectrophotometrically using
the Stanbio liquicolor β-hydroxybutyrate kit (Stanbio
Inc., Boerne, Texas).
Novel object recognition test
The novel object recognition test was performed after 38
days of treatment using the method described by
Dewachter et al. [20]. Briefly, mice were familiarized for
one hour to a Plexiglas open-field box (52 × 52 × 40 cm)
with black vertical walls and a translucent floor, dimly
illuminated by a lamp placed underneath the box. The
next day the animals were placed in the same box and sub-
mitted to a 10 minute acquisition trial. During this trial
mice were placed individually in the open field in the
presence of 2 × object A (orange barrel or green cube, sim-
ilar sized of ± 4 cm), and the duration (time AA) and the
frequency (Freq AA) exploring object A (when the animals
snout was directed towards the object at a distance of < 1
cm and the mice were actively sniffing in the direction ofNutrition & Metabolism 2005, 2:28 http://www.nutritionandmetabolism.com/content/2/1/28
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the object) was recorded by a computerized system (Etho-
vision, Noldus information Technology, Wageningen, the
Netherlands). During the 10 minute retention trial (sec-
ond trial) performed 3 hours later, a novel object (object
B, green cube or orange barrel) was placed together with
the familiar object (object A) into the open field. (Freq A
and Freq B and Time A and Time B, respectively). The rec-
ognition index (RI), defined as the ratio of the duration in
which the novel object was explored over the duration in
which both objects were explored (Time B/(Time A +
Time B) × 100), was used to measure non-spatial memory.
The duration and frequency object A was explored during
the acquisition trial (Time AA and Freq AA) was used to
measure curiosity.
Analytical techniques
The mice were anaesthetized with a mixture of Ketalar®
(Ketamin), Rompun® (Xylazin 2%) and Atropine (2:1:1)
and flushed trans-cardially with physiological serum at
4°C. This was performed to remove blood from the brain
vessels, a procedure which has no influence on organ
integrity. Blood was collected via a heart puncture and a 1
ml syringe in heparinized Eppendorf tubes. The brain was
removed from the cranium and hindbrain and forebrain
were separated with a cut in the coronal/frontal plane. The
forebrain was divided evenly into left and right hemi-
sphere by using a midline sagittal cut. One hemisphere of
each animal was homogenized using a Potter, a glass tube
(detergent free, 2 cm3) and a mechanical homogenizer
(650 rpm). A volume of 6.5 × 1/2 brain weight of freshly
prepared 20 mM Tris/HCl buffer (pH 8.5) with Proteinase
Inhibitors (1 tablet per 50 ml Tris/HCl buffer, Comple-
teTM, Roche, Mannheim, Germany) was used as
homogenization buffer. The homogenates were collected
in Beckman centrifuge tubes TLX and collected on ice
prior to centrifugation. Before the samples were centri-
fuged, 10 % of the sample was used for determination of
the total protein concentration of the homogenate
whereas 90 % of the samples were centrifuged to process
further for biochemistry. The supernatant (soluble frac-
tion containing secreted APP and amyloid peptides) was
separated from the pellet by centrifugation (membrane
fraction containing membrane-bound APP-fragments).
The supernatant was processed further by column chro-
matography to concentrate the amyloid peptides using
small reversed phase columns (C18-Sep-Pack Vac 3cc
cartridges, Waters, Massachusetts, MA). Amyloid peptides
were eluted with 75% A-TFA and the eluates were col-
lected in 2 ml tubes on ice. Eluates were freeze-dried in a
speedvac concentrator (Savant, Farmingdale, NY) over-
night and resolved in 240 µl of the sample diluent fur-
nished with the ELISA kits. To quantify the amount of
human Aβ40 and human Aβ42 in the soluble fraction of
the brain homogenates, commercially available Enzyme-
Linked-Immunosorbent-Assay (ELISA) kits were used (h
Amyloid Aβ40 or Aβ42 ELISA high sensitive, The Genetics
Company, Zurich, Switzerland). Quantification of the Aβ
content of the samples was obtained by comparing
absorbance to a standard curve made with synthetic Aβ40
or Aβ42. Total protein concentration in the brain
homogenate was measured using Bradford solution
(Pierce Inc.).
List of abbreviations
AD, Alzheimer's disease; APP, amyloid precursor protein;
Aβ, amyloid beta; SD, standard diet; KD, ketogenic diet;
CR, caloric restriction; BHB, β-hydroxybutyrate.
Competing interests
As co-founder of Accera, Inc., STH holds shares in an
organization and may gain or lose financially from the
publication of this manuscript. In addition, STH has
applied for patents relating to the content of the manu-
script and may gain or lose financially from publication of
this manuscript.
Acknowledgements
We thank the staff of Accera, Inc. for critical reading of this manuscript and 
helpful discussions.
References
1. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown
MJ, Hebert LE, Hennekens CH, Taylor JO: Prevalence of Alzhe-
imer's disease in a community population of older persons.
Higher than previously reported.  Jama 1989, 262:2551-2556.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer
disease in the US population: prevalence estimates using the
2000 census.  Arch Neurol 2003, 60:1119-1122.
3. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy.
Physiol Rev 2001, 81:741-766.
4. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL,
Raman R, Davies P, Masliah E, Williams DS, Goldstein LS: Axonopa-
thy and transport deficits early in the pathogenesis of Alzhe-
imer's disease.  Science 2005, 307:1282-1288.
5. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM:
Dietary fat intake and the risk of incident dementia in the
Rotterdam Study.  Ann Neurol 1997, 42:776-782.
6. Grant WB: Dietary links to Alzheimer's disease: 1999 update.
J Alzheimers Dis 1999, 1:197-201.
7. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS: Dietary
fat intake and 6-year cognitive change in an older biracial
community population.  Neurology 2004, 62:1573-1579.
8. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal
N, Schneider J, Wilson RS: Dietary fats and the risk of incident
Alzheimer disease.  Arch Neurol 2003, 60:194-200.
9. Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A,
Witteman JC, Breteler MM: Diet and risk of dementia: Does fat
matter?: The Rotterdam Study.  Neurology 2002, 59:1915-1921.
10. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint
GS, Sambamurti K, Duff K, Pappolla MA: Hypercholesterolemia
accelerates the Alzheimer's amyloid pathology in a trans-
genic mouse model.  Neurobiol Dis 2000, 7:321-331.
11. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri
G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM: Diet-induced insu-
lin resistance promotes amyloidosis in a transgenic mouse
model of Alzheimer's disease.  Faseb J 2004, 18:902-904.
12. Levin-Allerhand JA, Lominska CE, Smith JD: Increased amyloid-
levels in APPSWE transgenic mice treated chronically with
a physiological high-fat high-cholesterol diet.  J Nutr Health
Aging 2002, 6:315-319.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Nutrition & Metabolism 2005, 2:28 http://www.nutritionandmetabolism.com/content/2/1/28
Page 8 of 8
(page number not for citation purposes)
13. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC: Diet-induced
hypercholesterolemia enhances brain A beta accumulation
in transgenic mice.  Neuroreport 2002, 13:455-459.
14. George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K,
Evin G, Masters CL, Li QX: APP intracellular domain is
increased and soluble Abeta is reduced with diet-induced
hypercholesterolemia in a transgenic mouse model of Alzhe-
imer disease.  Neurobiol Dis 2004, 16:124-132.
15. Thio LL, Sitzwohl A, Trevathan E: The ketogenic diet.  In American
Academy of Pediatrics Pediatric Nutrition Handbook 5th edition. Edited
by: Kleinman RE. Elk Grove Village IL, American Academy of
Pediatrics; 2002. 
16. Kossoff EH, Krauss GL, McGrogan JR, Freeman JM: Efficacy of the
Atkins diet as therapy for intractable epilepsy.  Neurology 2003,
61:1789-1791.
17. Stafstrom CE: Dietary approaches to epilepsy treatment: old
and new options on the menu.  Epilepsy Curr 2004, 4:215-222.
18. Sullivan PG, Rippy NA, Dorenbos K, Concepcion RC, Agarwal AK,
Rho JM: The ketogenic diet increases mitochondrial uncou-
pling protein levels and activity.  Ann Neurol 2004, 55:576-580.
19. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu
A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B,
Van Leuven F: Early phenotypic changes in transgenic mice
that overexpress different mutants of amyloid precursor
protein in brain.  J Biol Chem 1999, 274:6483-6492.
20. Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, Van den
Haute C, Spittaels K, Umans L, Serneels L, Thiry E, Moechars D, Mer-
cken M, Godaux E, Van Leuven F: Neuronal deficiency of prese-
nilin 1 inhibits amyloid plaque formation and corrects
hippocampal long-term potentiation but not a cognitive
defect of amyloid precursor protein [V717I] transgenic
mice.  J Neurosci 2002, 22:3445-3453.
21. Marsset-Baglieri A, Fromentin G, Tome D, Bensaid A, Makkarios L,
Even PC: Increasing the protein content in a carbohydrate-
free diet enhances fat loss during 35% but not 75% energy
restriction in rats.  J Nutr 2004, 134:2646-2652.
22. Hellerstein MK: Carbohydrate-induced hypertriglyceridemia:
modifying factors and implications for cardiovascular risk.
Curr Opin Lipidol 2002, 13:33-40.
23. Rho JM, Sarnat HB, Sullivan PG, Robbins CA, Kim DW: Lack of long-
term histopathologic changes in brain and skeletal muscle of
mice treated with a ketogenic diet.  J Child Neurol 2004,
19:555-557.
24. Masoro EJ: Caloric restriction.  Aging (Milano) 1998, 10:173-174.
25. Bordone L, Guarente L: Calorie restriction, SIRT1 and metab-
olism: understanding longevity.  Nat Rev Mol Cell Biol 2005,
6:298-305.
26. Wickelgren I: Tracking insulin to the mind.  Science 1998,
280:517-519.
27. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P,
Xu H: Stimulation of beta-amyloid precursor protein traffick-
ing by insulin reduces intraneuronal beta-amyloid and
requires mitogen-activated protein kinase signaling.  J
Neurosci 2001, 21:2561-2570.
28. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner
MR, Selkoe DJ: Neurons regulate extracellular levels of amy-
loid beta-protein via proteolysis by insulin-degrading
enzyme.  J Neurosci 2000, 20:1657-1665.
29. Fishel MA, Watson GS, Montine TJ, Wang Q, Green PS, Kulstad JJ,
Cook DG, Peskind ER, Baker LD, Goldgaber D, Nie W, Asthana S,
Plymate SR, Schwartz MW, Craft S: Hyperinsulinemia Provokes
Synchronous Increases in Central Inflammation and {beta}-
Amyloid in Normal Adults.  Arch Neurol 2005, 62(10):1539-44.
30. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K,
Dolios G, Wang R, Hof PR, Pasinetti GM: Caloric restriction
attenuates beta-amyloid neuropathology in a mouse model
of Alzheimer's disease.  Faseb J 2005, 19:659-661.
31. Finn PF, Dice JF: Ketone bodies stimulate chaperone-mediated
autophagy.  J Biol Chem 2005, 280(27):25864-70.
32. Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson
GS, Hyde K, Chapman D, Craft S: Effects of beta-hydroxybu-
tyrate on cognition in memory-impaired adults.  Neurobiol
Aging 2004, 25:311-314.
33. Corbo RM, Scacchi R: Apolipoprotein E (APOE) allele distribu-
tion in the world. Is APOE*4 a 'thrifty' allele?  Ann Hum Genet
1999, 63 ( Pt 4):301-310.
34. Cordain L, Eades MR, Eades MD: Hyperinsulinemic diseases of
civilization: more than just Syndrome X.  Comp Biochem Physiol
A Mol Integr Physiol 2003, 136:95-112.
35. Henderson ST: High carbohydrate diets and Alzheimer's
disease.  Med Hypotheses 2004, 62:689-700.